Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients.

[1]  R. Riffenburgh,et al.  Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy. , 1997, The Journal of urology.

[2]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[3]  S. Levitt,et al.  Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy: A long term follow‐up , 1996 .

[4]  H. Zincke,et al.  Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. , 1995, The Journal of urology.

[5]  J. Oesterling,et al.  Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. , 1995, Urology.

[6]  R. B. Smith,et al.  The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.

[7]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[8]  H. Forman,et al.  CT screening for comorbid disease in patients with prostatic carcinoma: is it cost-effective? , 1994, AJR. American journal of roentgenology.

[9]  A. Partin,et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.

[10]  P. Humphrey,et al.  Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. , 1993, The Journal of urology.

[11]  J. Oesterling,et al.  The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. , 1993, JAMA.

[12]  M. Terris,et al.  Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[14]  J. Oesterling,et al.  Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. , 1991, The Journal of urology.

[15]  A. Rademaker,et al.  Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. , 1990, The Journal of urology.

[16]  G. Friedland,et al.  The role of imaging in screening for prostate cancer. A decision analysis perspective. , 1990, Investigative radiology.

[17]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.

[18]  W. Sause,et al.  Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG phase III study for A2 and B prostate carcinoma. , 1987, International journal of radiation oncology, biology, physics.

[19]  R. Stoller,et al.  Is Preoperative Computed Tomography Necessary in the Management of Patients Treated for Carcinoma of the Prostate by 125Iodine Interstitial Implantation and Bilateral Pelvic Lymphadenectomy? , 1987, American journal of clinical oncology.

[20]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[21]  P. Rubin,et al.  Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: implications of RTOG data for patient management and trial design and stratification. , 1992, International journal of radiation oncology, biology, physics.